본문 바로가기
KERD
논문KCI 등재

대사증후군과 치매

Metabolic Syndrome and Dementia

이애영
대한신경과학회 (Korean Neurological Association)|2011.08|대한신경과학회지 (Journal of the Korean Neurological Association)|제29권 제3호|pp. 159-164

2

조회

0

다운로드

8

인용

0

참고문헌

키워드

DementiaMetabolic syndromeInsulin resistanceHyperinsulinemia
주제분류신경과학

초록

The essential components of metabolic syndrome are insulin resistance, obesity, hypertension, and dyslipidemia. It is difficult to estimate its prevalence because several definitions of metabolic syndrome are in use. Although the exact cause-effect relation between metabolic syndrome and dementia is still controversial, the incidence of dementia and Alzheimer disease is relatively higher in individuals with metabolic syndrome than in those without it, regardless of mechanism. The pathophysiology of hyperinsulinemia and insulin resistance is responsible for causing cognitive decline or dementia in the elderly people, and It seems to be attributable to cerebral hypoperfusion and excessive Aβ deposition in the brain by insulin. Therefore, therapeutic intervention by modulating Aβ deposition and cerebral perfusion might be helpful to prevent patients with metabolic syndrome from getting cognitive dysfunction or dementia.

Abstract

The essential components of metabolic syndrome are insulin resistance, obesity, hypertension, and dyslipidemia. It is difficult to estimate its prevalence because several definitions of metabolic syndrome are in use. Although the exact cause-effect relation between metabolic syndrome and dementia is still controversial, the incidence of dementia and Alzheimer disease is relatively higher in individuals with metabolic syndrome than in those without it, regardless of mechanism. The pathophysiology of hyperinsulinemia and insulin resistance is responsible for causing cognitive decline or dementia in the elderly people, and It seems to be attributable to cerebral hypoperfusion and excessive Aβ deposition in the brain by insulin. Therefore, therapeutic intervention by modulating Aβ deposition and cerebral perfusion might be helpful to prevent patients with metabolic syndrome from getting cognitive dysfunction or dementia.

참고문헌 (52)

  1. Kylin E, "Studien uber das Hypertonie-hyperglyka ‘mie-Hyperurika’ miesyndrom", Zentralbl Inn Med, 44, pp.105~127 (1923)
  2. Alberti G, "Introduction to the metabolic syndrome", European Heart J, 7, pp.3~5 (2005)
  3. Frisardi V, "Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer’s disease", Aging Research Review, 9, pp.399~417 (2010)
  4. Alberti KG, "Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation", Diabet Med, 15, pp.539~553 (1998)
  5. Bailly J, "Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute", American Heart Association Conference on scientific issues related to definition, 2004, pp.109, 433~438
  6. Grundy SM, "American Heart Association: National Heart, Lung and Blood Institute; Diagnosis and management of the metabolic syndrome: an American Heart Association", National Heart, Lung, and Blood Institute Scientific Statement, 2005, pp.112, 2735~2752
  7. Grundy SM, "Metabolic syndrome: a multiplex cardiovascular risk factor", J Clin Endocrinol Metab, 92, pp.399~404 (2007)
  8. Maggi S, "Validity of the ATP III diagnostic criteria of the metabolic syndrome in an elderly Italian Caucasian population: the Italian Longitudinal Study on Aging", Atherosclerosis, 197, pp.877~882 (2008)
  9. Kwon HM, "Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people", Stroke, 37, pp.466~472 (2006)
  10. Reijmer YD, "Cognitive dysfunction in patients with type 2 diabetes", Diabetes Metab Res Rev, 26, pp.507~519 (2010)
  11. de la Monte SM, "Alzheimer's disease is type 3 diabetes-evidence reviewed", J Diabetes Sci Technol, 2, pp.1101~1113 (2008)
  12. Carlsson CM, "Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease", J Alzheimers Dis, 20, pp.711~722 (2010)
  13. de la Torre JC, "Critically attained threshold of cerebral hypoperfusion: can it cause Alzheimer's disease", Ann N Y Acad Sci, 903, pp.424~436 (2000)
  14. Qui WQ, "Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation", J Biol Chem, 273, pp.32730~32738 (1998)
  15. Farris W, "Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo", Proc Natl Acad Sci U S A, 100, pp.4162~4167 (2003)
  16. Niwa K, "Exogeneous Aβ1-42 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice", J Cereb Blood Flow Metab, 20, pp.1659~1668 (2000)
  17. Price JM, "Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production", Neurol Res, 23, pp.506~512 (2001)
  18. Thomas T, "Beta-amyloidmediated vasoactivity and vascular endothelial damage", Nature, 380, pp.168~171 (1996)
  19. Kivipelto M, "Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease", Arch Neurol, 62, pp.1556~1560 (2005)
  20. Whitmer RA, "Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study", BMJ, 330, pp.1360~1364 (2005)
  21. Whitmer RA, "Central obesity and increased risk of dementia more than three decades later", Neurology, 71, pp.1057~1064 (2008)
  22. Stewart R, "A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study", Arch Neurol, 62, pp.55~60 (2005)
  23. Barrett-Connor E, "Weight loss precedes dementia in community-dwelling older adults", J Nutr Health Aging, 2, pp.113~114 (1998)
  24. White H, "Weight change in Alzheimer’s disease", J Am Geriatr Soc, 44, pp.265~272 (1996)
  25. Solomon A, "Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later", Dement Geriatr Cogn Disord, 28, pp.75~80 (2009)
  26. Kivipelto M, "Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study", Neurology, 56, pp.1683~1689 (2001)
  27. Helzner EP, "Contribution of vascular risk factors to the progression of Alzheimer disease", Arch Neurol, 66, pp.343~348 (2009)
  28. Raffaitin C, "Metabolic syndrome and risk for incident Alzheimer’s disease or vascular dementia: the Three-City Study", Diabetes Care, 32, pp.169~174 (2009)
  29. Launer LJ, "Cholesterol and neuropathologic markers of AD: a population-based autopsy study", Neurology, 57, pp.1447~1452 (2001)
  30. Merched A, "Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease", Neurobiol Aging, 21, pp.27~30 (2000)
  31. Eiselein L, "Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis", Am J Physiol Heart Circ Physiol, 292, pp.2745~2753 (2007)
  32. Skoog I, "15-year longitudinal study of blood pressure and dementia", Lancet, 347, pp.1141~1145 (1996)
  33. Seshadri S, "Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study", Lancet Neurol, 6, pp.1106~1114 (2007)
  34. Kivipelto M, "Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study", Lancet Neurol, 5, pp.735~741 (2006)
  35. Launer LJ, "Midlife blood pressure and dementia: the Honolulu-Asia aging study", Neurobiol Aging, 21, pp.49~55 (2000)
  36. Li NC, "Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis", BMJ, 340, pp.5465~ (2010)
  37. Yasar S, "Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging", Neurobiol Aging, 26, pp.157~163 (2005)
  38. Obisesan TO, "Hypertension and cognitive function", Clin Geriatr Med, 25, pp.259~288 (2009)
  39. Forette F, "Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study", Arch Intern Med, 162, pp.2046~2052 (2002)
  40. Anderson C, "ONTARGET and TRANSCEND Investigators.Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies", Lancet Neurol, 10, pp.43~53 (2011)
  41. Solfrizzi V, "for the Italian Longitudinal Study on Aging Working Group. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging", Neurobiol Aging, 12, pp.1~10 (2009)
  42. Azizi F, "Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study", Diabetes Res Clin Pract, 61, pp.29~37 (2003)
  43. Ho RC, "Metabolic syndrome and cognitive decline in Chinese older adults: results from the singapore longitudinal ageing studies", Am J Geriatr Psychiatry, 16, pp.519~522 (2008)
  44. Dik MG, "Contribution of metabolic syndrome components to cognition in older individuals", Diabetes Care, 30, pp.2655~2660 (2007)
  45. van den Berg E, "The metabolic syndrome is associated with decelerated cognitive decline in the 1766 oldest old", Neurology, 69, pp.979~985 (2007)
  46. Yaffe K, "The metabolic syndrome and development of cognitive impairment among older women", Arch Neurol, 66, pp.324~328 (2009)
  47. Solfrizzi V, "Italian Longitudinal Study on Ageing Working Group. Metabolic syndrome and the risk of vascular dementia. The Italian Longitudinal Study on Aging", J Neurol Neurosurg Psychiatry, 81, pp.433~440 (2010)
  48. Solfrizzi V, "Italian Longitudinal Study on Aging Working Group. Vascular risk factors, incidence of MCI, and rates of progression to dementia", Neurology, 63, pp.1882~1891 (2004)
  49. Lopez OL, "Risk factors for mild cognitive impairment in the cardiovascular health study cognition study. Part 2", Arch Neurol, 60, pp.1394~1399 (2003)
  50. Alonso A, "Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study", J Neurol Neurosurg Psychiatry, 80, pp.1194~1201 (2009)
  51. Whitmer RA, "Midlife cardiovascular risk factors and risk of dementia in late life", Neurology, 64, pp.277~281 (2005)
  52. Roriz-Cruz M, "Cognitive impairment and frontal-subcortical geriatric syndrome are associated with metabolic syndrome in a stroke-free population", Neurobiol Aging, 28, pp.1723~1736 (2007)

이 간행물의 다른 논문 (27건)

앞관자엽극파의 쌍극자전류원: 방향의 임상적 의미박기종, 정석원, 김영수, 손승남, 김수경, 강희영, 최낙천, 임병훈, 권오영pp. 165-171Zonisamide 혹은 Topiramate를 사용한 뇌전증 환자에서 항뇌전증제 투약 전후 삶의 질 비교이장준, 김지언, 홍형기, 이상도, 박성파, 이세진pp. 172-176파킨슨 경도인지장애와 피질하 혈관성 경도인지장애의 인지기능의 비교최소영, 권오대, 김지혜, 장문선, 진영선pp. 177-183허혈성 뇌졸중 환자에서 클로피도그렐과 티클로피딘의 혈소판기능검사이수주, 이상준, 조성래, 김진옥, 김효정, 윤동준, 오건세, 고영채, 김재국pp. 184-191난치간질 환자의 해마용적 측정을 통한 해마 위축 확인박만석, 이승한, 강승호, 최성민, 김준태, 조기현, 남태승, 김명규, 김병채pp. 192-198
원문 보기